United States Biopsy Market, Volume & Forecast by Segments - Breast, Prostate, Lung, Liver & Thyroid

Researchmoz added Most up-to-date research on "United States Biopsy Market, Volume & Forecast by Segments - Breast, Prostate, Lung, Liver & Thyroid" to its huge collection of research reports.

Renub Research report titled “United States Biopsy Market, Volume & Forecast by Segments (Breast, Prostate, Lung, Liver and Thyroid), Companies (C. R. Bard, Inc.,  Becton, Dickinson and Company, B. Braun Melsungen AG, Cardinal Health, Inc., Olympus Corporation, FUJIFILM Holdings Corporation, Medtronic plc., Hologic, Inc)” provides a complete analysis of the United States Biopsy Market and Volume.

United States Biopsy Market will cross US$ 17 Billion by the year 2024 owing to the rising prevalence of cancer in the region. According to the World Health Organization, cancer cases are expected to surge 57% worldwide in the next 20 years. Biopsies are most often done to look for cancer; a biopsy is a sample of tissue taken from the body in order to examine it more closely. Further, growing patient awareness and the advancement in the biopsy techniques are also expected to fuel future growth of biopsy market in United States.

The World Cancer Report, produced by the WHO's specialized cancer agency and released on World Cancer Day, predicts new cancer cases will rise from an estimated 14 million annually in 2012 to 22 million within two decades. Over the same period, cancer deaths are predicted to rise from 8.2 million a year to 13 million.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1572616

By Segment – United States Biopsy Market and Volume 

On segment basis, Breast cancer biopsies accounts for the highest share in the United States Biopsy Market for the year 2017. While, in terms of Volume, Breast cancer biopsy has second highest share. Further, the report also covers the market aspects of Liver, Lung and Thyroid cancer biopsies. The Unites States Biopsy Market and Volume will experience a major growth during the forecast period owing to the increasing number of biopsy procedures and rising demand for minimally invasive procedures

All the 8 companies studied in the report have been studied from 4 points 

• Overview
• Business Strategy    
• Merger & Acquisition    
• Financial Insight

This 108 page report with 28 Figures and 2 Tables provides a complete analysis of the key Growth Drivers and Challenges, market, and their projections for the upcoming years.

Browse TOC @ https://www.researchmoz.us/united-states-biopsy-market-volume-forecast-by-segments-breast-prostate-lung-liver-thyroid-companies-report.html/toc

Segments Covered in the Report:

• Breast Cancer Biopsy
• Prostate Cancer Biopsy
• Lung Cancer Biopsy
• Liver Cancer Biopsy
• Thyroid Cancer Biopsy

Key Companies Covered in the Report: 

• C. R. Bard, Inc.
• Becton, Dickinson and Company
• B. Braun Melsungen AG
• Cardinal Health, Inc.
• Olympus Corporation
• FUJIFILM Holdings Corporation
• Medtronic plc.
• Hologic, Inc

United States – Biopsy Testing Market – Overview

United States Biopsy Test Market was more than US$ 15 Billion in 2014 and future seems to be much brighter. In the United States Biopsy Test Market, Breast Cancer is the most popular segment in 2014. Thyroid cancer stands at the last spot, but it is the most rapidly increasing type of cancer in the United States. However if we make the analysis from the Volume point then Prostate Cancer is the most popular segment. Increasing United States prevalence of cancer, geriatric population and increasing demand for minimally invasive procedures are expected to drive market growth during the forecast period.  

Renub Research report titled “United States – Biopsy Testing Market & Volume Analysis to 2020” provides a comprehensive assessment of the fast–evolving, high–growth of Biopsy Market. This 53 page report with 28 Figures and 1 Table analyses the United States Biopsy Test Market and Volume by 5 Top Cancer Segment, driving factors and challenges for Biopsy market.

The United States Biopsy Market has been analyzed from two view points

• United States Biopy Test Market & Forecast (2008 – 2020)
• United States Biopy Test Volume & Forecast (2008 – 2020)

The Top 5 Cancer Segments covered are:

1. Breast Cancer
2. Prostate Cancer
3. Liver Cancer
4. Lung Cancer
5. Thyroid Cancer

Global Liquid Biopsy Market Analysis by Cancer, Products, Circulating Biomarkers, Sample, Clinical Application, Regions & Companies

Researchmoz added Most up-to-date research on "Global Liquid Biopsy Market Analysis by Cancer, Products, Circulating Biomarkers, Sample, Clinical Application, Regions & Companies" to its huge collection of research reports.

Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024, witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world. Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies.

Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.

The cases of cancer increases very rapidly around the world owing to the adoption of unhealthy lifestyles and behaviors such as smoking, poor diet, physical inactivity etc. These rising cases of cancer will drive the liquid biopsy market to thrive in the coming years. As liquid biopsy is a simple and non-invasive technique it enables physicians to discover a range of information about patient’s tumor and provide clues about the treatment that a patient’s needs.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1866935

Renub Research report titled “Liquid Biopsy Market, Global Analysis by Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others), Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes), Sample (Plasma/Serum, Urine & Others), Clinical Application (Monitoring, Prognosis, Theranostics & Screening), Regions (North America, Europe, Asia-Pacific, Latin America and Middle East/Africa), Companies (Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics Inc., Genomic Health, NeoGenomics Laboratories, Qiagen)” provides a complete analysis of Global Liquid Biopsy Market.

By Cancer – Lung Cancer Controls the Liquid Biopsy Market

The report studies the market of the following cancer segments: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others. Lung cancer and Breast cancer together accounts for the considerable market share in the global liquid biopsy market.

Browse TOC @ https://www.researchmoz.us/liquid-biopsy-market-global-analysis-by-cancer-lung-breast-colorectal-etc-products-circulating-biomarkers-sample-clinical-application-regions-companies-report.html/toc

By Product – Majority of Liquid Biopsy Market held by Kits & Consumables 

The report studies the market of the following product segments: Kits & consumables, Instruments and Services. More than 90% of liquid biopsy market is comprised by kits & Consumables and Instruments.

By Circulating Biomarkers 

• The report studies the liquid biopsy market by Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes. Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) together holds significant market share

By Sample – Plasma/Serum accounts for the maximum market 

• In terms of Sample used for liquid biopsy, the global liquid biopsy market has been studied as Plasma/Serum, Urine and Others.

By Clinical Application – Screening Purpose leads the Liquid Biopsy Market

The report studies the market of the following clinical application segments: Monitoring, Prognosis, Theranostics & Screening.

By Region – North America and Europe will drive the Liquid Biopsy Market

North America and Europe together controls the Liquid Biopsy Market. In addition; the report also provides the complete geographical analysis of Asia-Pacific, Latin America and Middle East/Africa Liquid Biopsy Market.

Companies Analysis
Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics, Inc., Genomic Health, NeoGenomics Laboratories, Qiagen; which has been studied thoroughly in the report.

All the 9 Companies Studied in the Report have been Studied from 3 Points 

• Company Overview    
• Product Portfolio
• Financial Insight

This market research report provides a complete analysis of the Liquid Biopsy Market, Growth Drivers, Challenges, and their projections for the upcoming years.

By Cancer 

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Others 

By Product

• Kits & Consumables
• Instruments
• Services

By Circulating Biomarkers

• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (ctDNA)
• Exosomes

By Sample 

• Plasma/Serum
• Urine
• Others

By Clinical Application

• Monitoring
• Prognosis
• Theranostics
• Screening

By Regions

• North America
• Europe
• Asia-Pacific 
• Latin America
• Middle East/Africa

By Companies

• Thermo Fisher Scientific Inc.
• Roche Diagnostics
• Bio-Rad Laboratories Inc.
• Biocept Inc.
• Biocartis
• Myriad Genetics, Inc.
• Genomic Health
• NeoGenomics Laboratories
• Qiagen

Pancreatic Cancer Diagnostics Using Artificial Intelligence for Hospitals: Companies Mentioned Such As Numerate, BenevolentAI., Exscientia, twoXAR, Berg and Atomwise

Researchmoz added Most up-to-date research on "Pancreatic Cancer Diagnostics Using Artificial Intelligence for Hospitals: Companies Mentioned Such As Numerate, BenevolentAI., Exscientia, twoXAR, Berg and Atomwise" to its huge collection of research reports.

Pancreatic Cancer Diagnostics Using Artificial Intelligence for Hospitals

The 2017 study has 75 pages, 28 tables and figures. Worldwide markets are poised to achieve continuing growth as the artificial intelligence software increases diagnostic excellence, saving lives and lowering care delivery costs.

Automated cancer diagnostics are implemented with artificial intelligence. Systems are able to take a multi-disciplinary integrated approach to looking at imaging and scans. The analysis of patient records, looking for effectiveness of particular treatments is more work than a human can do, the quantity of data is too high, so the artificial intelligence is being used to do that. Systems are making a significant difference in saving lives.

Much of the hospital artificial intelligence market is centered on improving diagnosis and treatment of cancer through the visualization provided by radiology. The systems are able to track and analyze more data, more accurately than can the humans. Radiologists receive years of training. They are among the highest paid doctors, also among the first group of physicians utilizing artificial intelligence because of the complexity of the task to be done.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1354708

“Artificial intelligence expands into health care leveraging insight from radiological studies and diagnostics. Radiologists have a deluge of patient data that the artificial intelligence can manage in some ways. This contributes to earlier cancer diagnosis.”

Artificial Intelligence for Hospital Cancer Diagnostics Market Forecasts AI is set to become a sophisticated diagnostic aid, flagging images that humans should examine more closely, while leaving radiologists with more time for interacting with patients and medical staff. Hospital artificial intelligence market shipments at $1.7 billion in 2023 are forecast to reach $11.4 billion dollars, worldwide 2023.

Companies Profiled

Market Leaders

• General Electric
• IBM

Browse TOC @ https://www.researchmoz.us/pancreatic-cancer-diagnostics-using-artificial-intelligence-for-hospitals-market-shares-strategies-and-forecasts-worldwide-2017-to-2023-report.html/toc

Market Participants

• Alphabet / Google
• GlaxoSmithKline (GSK)
• Merck
• Prognos
• Quest Diagnostics
• Safeguard Scientifics
• Zebra

Companies Mentioned

• Drug discovery artificial intelligence
• Numerate
• BenevolentAI.
• Exscientia
• twoXAR
• Berg
• Atomwise

Global Hemostasis Diagnostics Market To Expand At A CAGR Of 8.3% Between 2017 - 2025, To Attract A Revenue Of US$3,979.5 Mn By 2025

Researchmoz added Most up-to-date research on "Global Hemostasis Diagnostics Market To Expand At A CAGR Of 8.3% Between 2017 - 2025, To Attract A Revenue Of US$3,979.5 Mn By 2025" to its huge collection of research reports.

This report on the global hemostasis diagnostics market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2015 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global hemostasis diagnostics market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the hemostasis diagnostics market such as augmentation in online services, increase in acceptance of disposable products and miniaturization. The key market indicators influencing global hemostasis diagnostics market taken into consideration including cost constraints and regulatory landscape. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global hemostasis diagnostics market. The report also highlights key events of the global hemostasis diagnostics industry. A porter’s five force analysis highlighting competitive landscape is also included in the report.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=173421

Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year. The year on year growth of global hemostasis diagnostics market for each segment is also reflected. Additionally, market related factors such as technological advancements, rise in POCT in developed countries, and cost reduction for hospitals and greater affordability for patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Hemostasis Diagnostics Market: Segmentation

Based on product type, the global hemostasis diagnostics market has been segmented into laboratory systems, consumables, and point-of-care testing systems. On the basis of test type the market has been segmented into prothrombin test time (PT), activated partial thromboplastin time (APTT), fibrinogen degradation products (FDP), activated clotting time, platelet aggregation test, d dimer, and others. Based on end-user, the market has been segmented into hospital/clinics, independent diagnostic laboratories, home care settings, and others. Hospitals segment is expected to remain dominant during the forecast period.

Browse TOC @ https://www.researchmoz.us/hemostasis-diagnostics-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019-report.html/toc

Geographically, the global hemostasis diagnostics market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.

Hemostasis Diagnostics Market: Competitive Landscape

The report also profiles major players in the hemostasis diagnostics market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the hemostasis diagnostics market is provided in the report. Key companies profiled in the report include Abbott Laboratories, Alere, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Nihon Kohden Corporation, Sysmex Corporation, Siemens Healthineers, Instrumentation Laboratory, Danaher Corporation (Beckman Coulter), and Grifols, S.A.

The global hemostasis diagnostics market has been segmented as follows:

Global Hemostasis Diagnostics Market, by Product

• Laboratory Systems
• Automated Systems
• Semi-automated Systems
• Manual Systems
• Consumables
• Point-of-Care Testing Systems

Global Hemostasis Diagnostics Market, By Test Type

• Prothrombin Test Time (PT)
• Activated partial thromboplastin time (APTT)
• Fibrinogen degradation products (FDP)
• Activated Clotting Time
• Platelet Aggregation Test
• D Dimer
• Others

Global Hemostasis Diagnostics Market, by End-user

• Hospital/Clinics
• Independent Diagnostic Laboratories
• Home Care Settings
• Others

 Global Hemostasis Diagnostics Market, by Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• Australia
• India
• Rest of Asia Pacific 
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• South Africa
• GCC
• Rest of Middle East & Africa

Global Drug of Abuse Testing Market Analysis By Top Players - Thermo Fisher Scientific, Abbott Laboratories, Quest Diagnostics and Laboratory Corporation of America (LabCorp)

Researchmoz added Most up-to-date research on "Global Drug of Abuse Testing Market Analysis By Top Players - Thermo Fisher Scientific, Abbott Laboratories, Quest Diagnostics and Laboratory Corporation of America (LabCorp)" to its huge collection of research reports.

Drug of Abuse Testing Market will be more than US$ 4.8 Billion opportunity by the end of year 2024. The market will grow due to growing drug users, raising use of drug of abuse testing in the companies, growth in cocaine uses and increase in government and non-government institutions initiatives globally. During 2006 to 2015, global drug user’s growth has grown nearly 23 percent. Opioids are one of the most dangerous drug type. Miss-use of pharmaceutical opioids has increased opioids related mortality in United States. United States is the leading country for opioids drug related deaths globally. 

Drug trafficking, mainly the cocaine and synthetic drugs are one of the driving forces for this market place as it has slowly but steadily crossing the countries boundaries and geographical regions.  For the first time in 2015, methamphetamine intercepted quantity in East and South-East Asia is higher than North American region. Drug of abuse testing is a method to detect drug addict person. It can perform by various methods such as urine testing, blood testing, oral testing and hair testing.  

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1828002

Renub Research report titled “Drug of Abuse Testing Market Global Forecast by Products (Consumable, Equipment - Immunoassay Analyzers, Breath Analyzers), Test Types (Urine, Blood, Oral, Hair), End Users/Setting Types (Employment, Lab based, Professional POC, Home OTC, Criminal Justice), Regions (North America, Europe, Asia Pacific, Middle East & Africa, Central & South America), Companies (Thermo Fisher Scientific, Abbott Laboratories, Quest Diagnostics, Laboratory Corporation of America (LabCorp), Danaher Corporation)” studies the global drug of abuse testing market and provides an all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.

By Products - Market Segmentation

Global drug of abuse testing market has been segmented by products as consumable and Equipment market. Consumable is playing major roles in global drug testing market. Immunoassay and Breath Analyzer are two most popular products in equipment segment. 

By Test Types - Urine Control Majority Share

Global drug of abuse testing market report has been studied by test types. Urine Test, Blood Test, Oral Test and Hair Test is covered to define the global market by test types. According to our analysis, we found that urine control majority share in this market place.

Browse TOC @ https://www.researchmoz.us/drug-of-abuse-testing-market-global-forecast-by-products-test-types-end-user-setting-types-regions-companies-report.html/toc

By End Users/ Setting Types - Market Segmentation

This report is also studying by end users/setting types such as Employment Testing; Lab Based Testing, Professional POC, Home OTC and Criminal Justice. Global rules and regulation regarding the pre-employment play the major role to boost drug of abuse testing market in the employment segment.

By Region - Market Segmentation

Drug of abuse testing market by region has been segmented into North America, Europe, Asia Pacific, Middle East & Africa and Central & South America. North America is a leading market place as there is large drug addict population, Pre-employment drug testing and increasing criminal cases. 

             

All companies in this report has been covered with the following view points

• Company Overview
• Company Initiatives/Strategy
• Financial Insight

Key Players 

 

Some of the key players in the global drug of abuse testing market include Thermo Fisher Scientific, Abbott Laboratories, Quest Diagnostics, Laboratory Corporation of America (LabCorp), Danaher Corporation.

The report has been analyzed from 8 major viewpoints

• Products Types
• Test Types
• End Users/Setting Types
• Regulatory Status
• Regions
• Company 
• Growth drivers
• Challenges

Segmentation based on Products

• Consumable
• Equipment
• Immunoassay Analyzers
• Breath Analyzers

Segmentation based on Test Types

• Urine
• Blood
• Oral
• Hair

Segmentation based on End Users/Setting Types

• Employment
• Lab based
• Professional POC
• Home OTC
• Criminal Justice

Segmentation based on Region

• North America
• Europe
• Asia-Pacific 
• Middle East & Africa 
• Central & South America 

Companies Analysis

• Thermo Fisher Scientific
• Abbott Laboratories
• Quest Diagnostics
• Laboratory Corporation of America (LabCorp)
• Danaher Corporation.

United States Biopsy Market Booming with the Major Players Like C. R. Bard, Inc., Becton, Dickinson and Company, B. Braun Melsungen AG and Cardinal Health, Inc.

Researchmoz added Most up-to-date research on "United States Biopsy Market Booming with the Major Players Like C. R. Bard, Inc., Becton, Dickinson and Company, B. Braun Melsungen AG and Cardinal Health, Inc." to its huge collection of research reports.

Renub Research report titled “United States Biopsy Market, Volume & Forecast by Segments (Breast, Prostate, Lung, Liver and Thyroid), Companies (C. R. Bard, Inc.,  Becton, Dickinson and Company, B. Braun Melsungen AG, Cardinal Health, Inc., Olympus Corporation, FUJIFILM Holdings Corporation, Medtronic plc., Hologic, Inc)” provides a complete analysis of the United States Biopsy Market and Volume.

United States Biopsy Market will cross US$ 17 Billion by the year 2024 owing to the rising prevalence of cancer in the region. According to the World Health Organization, cancer cases are expected to surge 57% worldwide in the next 20 years. Biopsies are most often done to look for cancer; a biopsy is a sample of tissue taken from the body in order to examine it more closely. Further, growing patient awareness and the advancement in the biopsy techniques are also expected to fuel future growth of biopsy market in United States.

The World Cancer Report, produced by the WHO's specialized cancer agency and released on World Cancer Day, predicts new cancer cases will rise from an estimated 14 million annually in 2012 to 22 million within two decades. Over the same period, cancer deaths are predicted to rise from 8.2 million a year to 13 million.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1572616

By Segment – United States Biopsy Market and Volume 

On segment basis, Breast cancer biopsies accounts for the highest share in the United States Biopsy Market for the year 2017. While, in terms of Volume, Breast cancer biopsy has second highest share. Further, the report also covers the market aspects of Liver, Lung and Thyroid cancer biopsies. The Unites States Biopsy Market and Volume will experience a major growth during the forecast period owing to the increasing number of biopsy procedures and rising demand for minimally invasive procedures

All the 8 companies studied in the report have been studied from 4 points 

• Overview
• Business Strategy    
• Merger & Acquisition    
• Financial Insight

This 108 page report with 28 Figures and 2 Tables provides a complete analysis of the key Growth Drivers and Challenges, market, and their projections for the upcoming years.

Browse TOC @ https://www.researchmoz.us/united-states-biopsy-market-volume-forecast-by-segments-breast-prostate-lung-liver-thyroid-companies-report.html/toc

Segments Covered in the Report:

• Breast Cancer Biopsy
• Prostate Cancer Biopsy
• Lung Cancer Biopsy
• Liver Cancer Biopsy
• Thyroid Cancer Biopsy

Key Companies Covered in the Report: 

• C. R. Bard, Inc.
• Becton, Dickinson and Company
• B. Braun Melsungen AG
• Cardinal Health, Inc.
• Olympus Corporation
• FUJIFILM Holdings Corporation
• Medtronic plc.
• Hologic, Inc

United States – Biopsy Testing Market – Overview

United States Biopsy Test Market was more than US$ 15 Billion in 2014 and future seems to be much brighter. In the United States Biopsy Test Market, Breast Cancer is the most popular segment in 2014. Thyroid cancer stands at the last spot, but it is the most rapidly increasing type of cancer in the United States. However if we make the analysis from the Volume point then Prostate Cancer is the most popular segment. Increasing United States prevalence of cancer, geriatric population and increasing demand for minimally invasive procedures are expected to drive market growth during the forecast period.  

Renub Research report titled “United States – Biopsy Testing Market & Volume Analysis to 2020” provides a comprehensive assessment of the fast–evolving, high–growth of Biopsy Market. This 53 page report with 28 Figures and 1 Table analyses the United States Biopsy Test Market and Volume by 5 Top Cancer Segment, driving factors and challenges for Biopsy market.

The United States Biopsy Market has been analyzed from two view points

• United States Biopy Test Market & Forecast (2008 – 2020)
• United States Biopy Test Volume & Forecast (2008 – 2020)

The Top 5 Cancer Segments covered are:

1. Breast Cancer
2. Prostate Cancer
3. Liver Cancer
4. Lung Cancer
5. Thyroid Cancer

Global Liquid Biopsy Market Competition By Players With Rising Growth: Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc. and Biocept Inc.

Researchmoz added Most up-to-date research on "Global Liquid Biopsy Market Competition By Players With Rising Growth: Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc. and Biocept Inc." to its huge collection of research reports.

Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024, witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world. Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies.

Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.

The cases of cancer increases very rapidly around the world owing to the adoption of unhealthy lifestyles and behaviors such as smoking, poor diet, physical inactivity etc. These rising cases of cancer will drive the liquid biopsy market to thrive in the coming years. As liquid biopsy is a simple and non-invasive technique it enables physicians to discover a range of information about patient’s tumor and provide clues about the treatment that a patient’s needs.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1866935

Renub Research report titled “Liquid Biopsy Market, Global Analysis by Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others), Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes), Sample (Plasma/Serum, Urine & Others), Clinical Application (Monitoring, Prognosis, Theranostics & Screening), Regions (North America, Europe, Asia-Pacific, Latin America and Middle East/Africa), Companies (Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics Inc., Genomic Health, NeoGenomics Laboratories, Qiagen)” provides a complete analysis of Global Liquid Biopsy Market.

By Cancer – Lung Cancer Controls the Liquid Biopsy Market

The report studies the market of the following cancer segments: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others. Lung cancer and Breast cancer together accounts for the considerable market share in the global liquid biopsy market.

By Product – Majority of Liquid Biopsy Market held by Kits & Consumables 

The report studies the market of the following product segments: Kits & consumables, Instruments and Services. More than 90% of liquid biopsy market is comprised by kits & Consumables and Instruments.

Browse TOC @ https://www.researchmoz.us/liquid-biopsy-market-global-analysis-by-cancer-lung-breast-colorectal-etc-products-circulating-biomarkers-sample-clinical-application-regions-companies-report.html/toc

By Circulating Biomarkers 

• The report studies the liquid biopsy market by Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes. Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) together holds significant market share

By Sample – Plasma/Serum accounts for the maximum market 

• In terms of Sample used for liquid biopsy, the global liquid biopsy market has been studied as Plasma/Serum, Urine and Others.

By Clinical Application – Screening Purpose leads the Liquid Biopsy Market

The report studies the market of the following clinical application segments: Monitoring, Prognosis, Theranostics & Screening.

By Region – North America and Europe will drive the Liquid Biopsy Market

North America and Europe together controls the Liquid Biopsy Market. In addition; the report also provides the complete geographical analysis of Asia-Pacific, Latin America and Middle East/Africa Liquid Biopsy Market.

Companies Analysis

Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics, Inc., Genomic Health, NeoGenomics Laboratories, Qiagen; which has been studied thoroughly in the report.

All the 9 Companies Studied in the Report have been Studied from 3 Points 

• Company Overview    
• Product Portfolio
• Financial Insight

This market research report provides a complete analysis of the Liquid Biopsy Market, Growth Drivers, Challenges, and their projections for the upcoming years.

By Cancer 

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Others 

By Product

• Kits & Consumables
• Instruments
• Services

By Circulating Biomarkers

• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (ctDNA)
• Exosomes

By Sample 

• Plasma/Serum
• Urine
• Others

By Clinical Application

• Monitoring
• Prognosis
• Theranostics
• Screening

By Regions

• North America
• Europe
• Asia-Pacific 
• Latin America
• Middle East/Africa

By Companies

• Thermo Fisher Scientific Inc.
• Roche Diagnostics
• Bio-Rad Laboratories Inc.
• Biocept Inc.
• Biocartis
• Myriad Genetics, Inc.
• Genomic Health
• NeoGenomics Laboratories
• Qiagen

Detailed Overview Of Global Therapies And Diagnostics For Ovarian Cancer Market By Device, Application and Region

Researchmoz added Most up-to-date research on "Detailed Overview Of Global Therapies And Diagnostics For Ovarian Cancer Market By Device, Application and Region" to its huge collection of research reports.

Global Therapies And Diagnostics For Ovarian Cancer Market

This report will provide a detailed overview of ovarian cancer, highlighting treatment guidelines with information on the current and potential global market for ovarian cancer and treatments and testing technologies with detailed analysis of the competitive landscape, including new potential markets for novel products, diagnostics and therapeutics development.

The report covers the regulatory environment, current and new technologies, ovarian cancer incidence, market projections and market share along with the latest trends and new developments, recent approvals, the research and development pipeline, and blockbuster drugs. It also covers global and regional markets for ovarian cancer diagnostics and therapies, providing reasons for variations in the growth of the industry across regions.

The report also analyzes the competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include AbbVie Inc, Astra Zeneca, Bristol-Myers Squibb Company, Celgene Corp., Clovis Oncology, Eli Lilly and Company, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Janssen Pharmaceuticals, Inc., Merck & Company, Inc., Myriad Genetics Inc., Novartis AG, Pfizer, Inc., Quest Diagnostics Inc., Roche Holding AG and Tesaro, Inc.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1704823

Report Includes:
- 28 data tables and 9 additional tables
- A comprehensive analysis of the ophthalmic device market by reviewing recent advances in diagnostic, surgical, and implantation devices that can be used to treat prevalent eye conditions.
- Analyses of global market trends with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022.
- Breakdowns of the market by device, application, and region.
- Analysis of the recent advances in ophthalmic medical devices and their potential impact on the medical device industry.
- Evaluation of the markets dynamics, specifically growth drivers, restraints, and opportunities.
- Company profiles of major players in the market, including AbbVie Inc., Bristol-Myers Squibb, Clovis Oncology, Inc., Eli Lilly and Company and Pfizer Inc.

Browse TOC @ https://www.researchmoz.us/therapies-and-diagnostics-for-ovarian-cancer-global-markets-to-2022-report.html/toc

Reasons for Doing This Study
This study was conducted to provide detailed information regarding screening, testing and treatment options for ovarian disorders and cancer. There is an increasing need for new and innovative technologies, while this industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer diagnostic and treatment strategies. This study looks at most types of diagnostic and treatment strategies for the clinical management of ovarian disorders and related cancers.

This BCC Research market research report will increase the awareness of current and emerging drugs and technologies for ovarian cancers, including therapeutics, chemotherapy and surgical therapy."

"Report Scope:
This report will provide a detailed overview of ovarian cancer, highlighting treatment guidelines with information on the current and potential global market for ovarian cancer and treatments and testing technologies with detailed analysis of the competitive landscape, including new potential markets for novel products, diagnostics and therapeutics development.

The report covers the regulatory environment, current and new technologies, ovarian cancer incidence, market projections and market share along with the latest trends and new developments, recent approvals, the research and development pipeline, and blockbuster drugs. It also covers global and regional markets for ovarian cancer diagnostics and therapies, providing reasons for variations in the growth of the industry across regions.

The report also analyzes the competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include AbbVie Inc, Astra Zeneca, Bristol-Myers Squibb Company, Celgene Corp., Clovis Oncology, Eli Lilly and Company, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Janssen Pharmaceuticals, Inc., Merck & Company, Inc., Myriad Genetics Inc., Novartis AG, Pfizer, Inc., Quest Diagnostics Inc., Roche Holding AG and Tesaro, Inc.

Report Includes:
- 28 data tables and 9 additional tables
- A comprehensive analysis of the ophthalmic device market by reviewing recent advances in diagnostic, surgical, and implantation devices that can be used to treat prevalent eye conditions.
- Analyses of global market trends with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022.
- Breakdowns of the market by device, application, and region.
- Analysis of the recent advances in ophthalmic medical devices and their potential impact on the medical device industry.
- Evaluation of the markets dynamics, specifically growth drivers, restraints, and opportunities.
- Company profiles of major players in the market, including AbbVie Inc., Bristol-Myers Squibb, Clovis Oncology, Inc., Eli Lilly and Company and Pfizer Inc."